120
Participants
Start Date
February 4, 2025
Primary Completion Date
July 30, 2027
Study Completion Date
July 30, 2027
BGB-21447
Administered orally.
Fulvestrant
Administered via intramuscular injection.
BGB-43395
Administered orally.
RECRUITING
Fudan University Shanghai Cancer Centerpudong, Shanghai
RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
RECRUITING
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou
RECRUITING
Hoag Memorial Presbyterian, Newport Beach
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
Md Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Fred Hutchinson Cancer Research Center, Seattle
RECRUITING
Saint Vincents Hospital Sydney, Darlinghurst
RECRUITING
Calvary Mater Newcastle, Waratah
RECRUITING
Sunshine Coast University Private Hospital, Birtinya
RECRUITING
Peter Maccallum Cancer Centre, Melbourne
RECRUITING
Western Health Sunshine Hospital, St Albans
RECRUITING
Linear Clinical Research, Nedlands
Lead Sponsor
BeiGene
INDUSTRY